EnteroTarget

EnteroTarget is a clinical-stage biotechnology company and a spinout from the University of Copenhagen, established in 2018. The company focuses on developing novel therapeutic strategies for inflammatory bowel disease (IBD) by targeting the regeneration of the colonic epithelial lining. Its lead product candidate, EnteroCalm, utilizes topically acting insulin to target the intestinal epithelial insulin receptor, achieving an anti-inflammatory effect without affecting immune cells. EnteroTarget is advancing both a rectal enema formulation and an oral delayed-release capsule formulation utilizing its proprietary EnteroShuttle delivery technology. The company's primary target indications include ulcerative colitis, pouchitis, and Crohn's disease.